138 related articles for article (PubMed ID: 3291602)
1. Pharmacological studies on androgen suppression in therapy of prostate carcinoma.
Sandow J; von Rechenberg W; Engelbart K
Am J Clin Oncol; 1988; 11 Suppl 1():S6-10. PubMed ID: 3291602
[TBL] [Abstract][Full Text] [Related]
2. The different mechanisms for suppression of pituitary and testicular function.
Sandow J; Engelbart K; von Rechenberg W
Med Biol; 1986; 63(5-6):192-200. PubMed ID: 3010006
[TBL] [Abstract][Full Text] [Related]
3. Rat prostatic weight regression in reaction to ketoconazole, cyproterone acetate, and RU 23908 as adjuncts to a depot formulation of gonadotropin-releasing hormone analogue.
Lamberts SW; Uitterlinden P; de Jong FH
Cancer Res; 1988 Nov; 48(21):6063-8. PubMed ID: 2844399
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
5. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
[TBL] [Abstract][Full Text] [Related]
6. Rationale for blockade of adrenal as well as testicular androgens in the treatment of advanced prostate cancer.
Geller J
Semin Oncol; 1985 Mar; 12(1 Suppl 1):28-35. PubMed ID: 3883502
[TBL] [Abstract][Full Text] [Related]
7. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
Nishiyama T; Hashimoto Y; Takahashi K
Clin Cancer Res; 2004 Nov; 10(21):7121-6. PubMed ID: 15534082
[TBL] [Abstract][Full Text] [Related]
8. Histological and functional changes of the testis tissue during GnRH agonist treatment of prostatic cancer.
Huhtaniemi I; Nikula H; Parvinen M; Rannikko S
Am J Clin Oncol; 1988; 11 Suppl 1():S11-5. PubMed ID: 2839028
[TBL] [Abstract][Full Text] [Related]
9. Antifertility effects of luteinizing hormone-releasing hormone (LHRH) agonists.
Labrie F; Bélanger A; Kelly PA; Séguin C; Cusan L; Lefebvre FA; Reeves JJ; Lemay A; Faure N; Gourdeau Y; Raynaud JP
Prog Clin Biol Res; 1981; 74():273-91. PubMed ID: 6275404
[TBL] [Abstract][Full Text] [Related]
10. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
Borgmann V; al-Abadi H; Nagel R
Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
[TBL] [Abstract][Full Text] [Related]
11. Duration of testosterone suppression after a 9.45 mg implant of the GnRH-analogue buserelin in patients with localised carcinoma of the prostate a 12-month follow-up study.
Pettersson B; Varenhorst E; Petas A; Sandow J
Eur Urol; 2006 Sep; 50(3):483-9. PubMed ID: 16626856
[TBL] [Abstract][Full Text] [Related]
12. Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells.
Attardi BJ; Burgenson J; Hild SA; Reel JR
Mol Cell Endocrinol; 2004 Jul; 222(1-2):121-32. PubMed ID: 15249132
[TBL] [Abstract][Full Text] [Related]
13. Innovative approaches to the hormonal treatment of advanced prostate cancer.
Trachtenberg J
Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
[TBL] [Abstract][Full Text] [Related]
14. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
15. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
16. Use of cyproterone acetate in prostate cancer.
Goldenberg SL; Bruchovsky N
Urol Clin North Am; 1991 Feb; 18(1):111-22. PubMed ID: 1825143
[TBL] [Abstract][Full Text] [Related]
17. [Cancer of the prostate: biologic bases for the use of an antiandrogen in its treatment].
Raynaud JP; Coussediere D; Moguilewsky M; Pottier J; Labrie F
Bull Cancer; 1986; 73(1):36-46. PubMed ID: 3779121
[TBL] [Abstract][Full Text] [Related]
18. Significant role of 5 alpha-reductase on feedback effects of androgen in rat anterior pituitary cells demonstrated with a nonsteroidal 5 alpha-reductase inhibitor ONO-3805.
Nagamoto A; Noguchi K; Murai T; Kinoshita Y
J Androl; 1994; 15(6):521-7. PubMed ID: 7721654
[TBL] [Abstract][Full Text] [Related]
19. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
Rittmaster R; Hahn RG; Ray P; Shannon JB; Wurzel R
Urology; 2008 Oct; 72(4):808-12. PubMed ID: 18718641
[TBL] [Abstract][Full Text] [Related]
20. Testosterone recovery after prolonged androgen suppression in patients with prostate cancer.
Yoon FH; Gardner SL; Danjoux C; Morton G; Cheung P; Choo R
J Urol; 2008 Oct; 180(4):1438-43; discussion 1443-4. PubMed ID: 18710743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]